BAM-15

Quick Facts

Introduction

BAM-15 is a small-molecule mitochondrial uncoupler studied in preclinical metabolic research. Mitochondrial uncouplers dissipate the proton gradient that mitochondria normally use to make ATP, so the energy from fuel is released as heat instead of being captured — a process studied as a way to increase energy expenditure and burn substrate. BAM-15 belongs to the same broad research conversation as other non-hormonal metabolic agents such as the ERR agonist SLU-PP-332 and the NNMT inhibitor 5-Amino-1MQ.

The reason BAM-15 attracted attention is that earlier uncouplers — most notoriously 2,4-dinitrophenol (DNP) — carried a dangerously narrow margin because they also depolarized the plasma membrane, not just the mitochondrial inner membrane. BAM-15 was characterized in research as a protonophore that acts comparatively selectively on the mitochondrial membrane, which is the central reason it became a tool for studying 'controlled' uncoupling. It is described here purely as a research compound, not as a safe or approved agent.

This profile covers what BAM-15 is, its molecular characteristics as a non-peptide protonophore, the uncoupling mechanism it engages, the metabolic research it appears in, and how it compares with related metabolic compounds and mitochondrial agents such as MOTS-c. Related entries are catalogued in the peptide database.

What is BAM-15?

BAM-15 is a synthetic small-molecule protonophore — a lipophilic compound that can ferry protons across the mitochondrial inner membrane, short-circuiting the gradient that the electron-transport chain builds up. By providing a 'leak' for protons, it forces the mitochondria to oxidize more fuel to maintain that gradient, increasing oxygen consumption and heat production.

It is a non-peptide, with no amino-acid sequence, and is handled like a classical drug-discovery scaffold rather than a reconstituted peptide. Its defining, much-cited property in the research literature is that it uncouples mitochondria while largely sparing the plasma-membrane potential — distinguishing it from older, less selective uncouplers.

Molecular and structural characteristics

BAM-15 (chemically a fluorinated aromatic compound) is a weak-acid protonophore: its structure delocalizes a negative charge well enough that it can pick up a proton on one side of the mitochondrial membrane, cross the lipid bilayer in its neutral form, and release the proton on the other side. The molecular features that make it relatively selective for mitochondria over the plasma membrane are the main subject of its structure–activity research.

Because it is not a peptide, BAM-15 does not require the aqueous reconstitution workflow used for injectable peptides catalogued in the peptide database; in vitro studies typically dissolve it in an organic co-solvent.

Mechanism of action

BAM-15 works by uncoupling oxidative phosphorylation. Normally the electron-transport chain pumps protons out of the mitochondrial matrix, creating a gradient (the proton-motive force) that ATP synthase uses to make ATP. As a protonophore, BAM-15 lets protons flow back into the matrix bypassing ATP synthase, so the energy is dissipated as heat. The mitochondria respond by oxidizing more fuel to try to rebuild the gradient — the basis of increased energy expenditure.

The property that defines BAM-15 in the literature is its comparative selectivity for the mitochondrial inner membrane. Research characterizing it reported that, unlike the classic uncoupler FCCP and the historically dangerous DNP, BAM-15 does not strongly depolarize the plasma membrane at active concentrations. This is studied as the reason it can increase respiration with a wider apparent margin in preclinical models — though this remains a research observation, not an established safety claim.

Mechanistically, BAM-15 sits at the opposite end of the spectrum from compounds that build mitochondrial capacity. Where SLU-PP-332 increases mitochondrial biogenesis transcriptionally and MOTS-c modulates mitochondrial stress signaling, BAM-15 acts acutely on the existing mitochondria by making them less efficient on purpose. Researchers study these as complementary levers on cellular energetics.

• Acts as a proton ionophore across the mitochondrial inner membrane.
• Uncouples electron transport from ATP synthesis.
• Increases substrate oxidation and oxygen consumption.
• Releases fuel energy as heat (thermogenesis-like effect).
• Reportedly spares the plasma-membrane potential vs older uncouplers.

Metabolic and body-composition research

The defining research context for BAM-15 is diet-induced obesity and insulin resistance. Preclinical rodent studies have reported that administration is associated with reduced body weight and adiposity in diet-challenged animals, with the effect attributed to increased energy expenditure rather than to appetite suppression. Because uncoupling burns substrate directly, body-weight effects in these models occurred largely independent of food intake.

A second prominent strand of research concerns insulin sensitivity and metabolic health. By increasing substrate oxidation and reducing ectopic lipid accumulation, controlled mitochondrial uncoupling has been studied for associations with improved glucose handling and reduced hepatic fat in research models. This places BAM-15 alongside other compounds studied for fat-loss and metabolic endpoints, including 5-Amino-1MQ.

Mitochondrial and tissue-protection research

Beyond body composition, mild mitochondrial uncoupling is studied as a way to reduce the production of reactive oxygen species (ROS). A high proton-motive force can promote electron leak and ROS formation, so modestly lowering the gradient with a protonophore is examined for associations with reduced oxidative stress — a concept relevant to ischemia–reperfusion injury and other tissue-stress models.

This protective framing links BAM-15 conceptually to mitochondria-targeted research compounds approached from other angles, such as the cardiolipin-associated peptide SS-31 and the mitochondrial-derived peptide Humanin. Each is studied for mitochondrial resilience through a different mechanism, and researchers treat them as distinct but complementary probes.

Comparison: BAM-15 vs SLU-PP-332 vs 5-Amino-1MQ

BAM-15 is most usefully compared with two other non-hormonal metabolic research compounds: SLU-PP-332, an ERR transcriptional agonist, and 5-Amino-1MQ, an NNMT inhibitor. All three are studied for metabolic and body-composition endpoints through distinct molecular mechanisms.

The unifying theme is increasing energy expenditure or remodeling metabolism without primarily suppressing appetite — but BAM-15 is unique in acting acutely on existing mitochondria rather than reprogramming them. Full entries for SLU-PP-332 and 5-Amino-1MQ are available, and related compounds are catalogued in the peptide database.

Half-life and pharmacokinetic considerations

As a lipophilic small molecule, BAM-15 has pharmacokinetics distinct from peptides; its lipophilicity is essential to its ability to shuttle protons across membranes. Preclinical research has used repeated administration to sustain its metabolic effects, and medicinal-chemistry work on uncoupler analogues has focused on tuning exposure and selectivity.

Because the biological effect of an uncoupler scales with the concentration achieved at the mitochondrial membrane, the relationship between exposure and effect is steep — too little does nothing, while too much risks excessive uncoupling. This narrow concentration-dependence is a core interpretive caution in BAM-15 research, and precise human pharmacokinetic parameters are not established.

Reconstitution and handling considerations

Unlike lyophilized peptides, BAM-15 is a small molecule and is generally dissolved in an organic co-solvent (such as DMSO) for in vitro stock solutions rather than reconstituted in water. Handling emphasizes accurate weighing and protection from light and moisture.

Because the peptide reconstitution workflow does not directly apply, the reconstitution calculator and reconstitution guide are most relevant for the peptide compounds it is compared against rather than for BAM-15 itself.

• Treat as a small molecule, not a reconstituted peptide.
• Dissolve in an appropriate organic co-solvent for stock solutions.
• Weigh accurately; uncoupler effects are steeply concentration-dependent.
• Protect prepared stocks from light and excess warmth.

Storage considerations

Powdered BAM-15 is most stable kept frozen at −20 °C, dry and away from light. Prepared stock solutions are typically refrigerated or frozen, kept dark, and protected from repeated freeze–thaw cycles; aliquoting reduces how often a given stock is cycled.

Research limitations

BAM-15 is an early-stage research compound, and mitochondrial uncoupling as a class carries a historically narrow margin of safety because the line between beneficial energy expenditure and harmful metabolic disruption is concentration-dependent. Its reported selectivity for the mitochondrial over the plasma membrane is a research finding, not an established human safety profile, and human data are not available. It is described here strictly for research reference.

• Evidence is largely preclinical; human data are not established.
• Mitochondrial uncouplers have a historically narrow safety margin.
• Effects are steeply concentration-dependent.
• Reported plasma-membrane selectivity is a research finding, not a safety guarantee.
• It is not an approved therapy and is described solely for research reference.

Frequently Asked Questions

Related Research Profiles

References

1. Kenwood BM, Weaver JL, Bajwa A, et al. Identification of a novel mitochondrial uncoupler that does not depolarize the plasma membrane. Molecular Metabolism. 2014.
2. Alexopoulos SJ, Chen SY, Brandon AE, et al. Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice. Nature Communications. 2020.
3. Childress ES, Alexopoulos SJ, Hoehn KL, Santos WL. Small molecule mitochondrial uncouplers and their therapeutic potential. Journal of Medicinal Chemistry. 2018.